Literature DB >> 3346059

Clinical implications of primary aldosteronism with resistant hypertension.

E L Bravo1, F M Fouad-Tarazi, R C Tarazi, M Pohl, R W Gifford, D G Vidt.   

Abstract

Twenty-eight patients with resistant hypertension were found to have primary aldosteronism; 25 had solitary adenoma and 3 had adrenal hyperplasia. All were severely hypertensive despite receiving three or more antihypertensive agents, including conventional doses of diuretics, sympatholytics, and vasodilators. Hypervolemia (24 patients) or normovolemia (2 patients) despite severe diastolic hypertension was the hallmark in 26 patients. Adequate salt and water depletion alone with spironolactone (200 mg/day) and hydrochlorothiazide (50-100 ng/day) reduced arterial pressure in all. Twenty-two patients had surgical removal of a solitary adenoma. Over 1 to 2 years of follow-up, 13 were normotensive without medication, and six required hydrochlorothiazide and three hydrochlorothiazide plus a beta-blocker to normalize blood pressure. Blood pressure response to surgery had no relation to either duration or severity of hypertension. Six patients (three with hyperplasia, three with adenoma) have continued diuretic therapy and are normokalemic and normotensive. These results indicate that primary aldosteronism can be associated with sever and drug-resistant hypertension, that maintained hypervolemia is the reason for resistance to therapy, that sustained volume depletion is the most important therapeutic goal for these patients, and that cure can be achieved despite prolonged and severe hypertension.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3346059     DOI: 10.1161/01.hyp.11.2_pt_2.i207

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  9 in total

Review 1.  Medical management of primary hyperaldosteronism.

Authors:  E L Bravo
Journal:  Curr Hypertens Rep       Date:  2001-10       Impact factor: 5.369

2.  Hypertensive Crises.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  1999-06

Review 3.  Aldosterone and specific aldosterone receptor antagonists in hypertension and cardiovascular disease.

Authors:  Emmanuel L Bravo
Journal:  Curr Hypertens Rep       Date:  2003-04       Impact factor: 5.369

Review 4.  Molecular and clinical investigations in patients with low-renin hypertension.

Authors:  Isla S Mackenzie; Morris J Brown
Journal:  Clin Exp Nephrol       Date:  2008-08-15       Impact factor: 2.801

5.  Intrarenal hemodynamics in primary aldosteronism before and after treatment.

Authors:  Leonardo A Sechi; Alessandro Di Fabio; Massimo Bazzocchi; Alessandro Uzzau; Cristiana Catena
Journal:  J Clin Endocrinol Metab       Date:  2009-01-13       Impact factor: 5.958

6.  Primary aldosteronism: difference in clinical presentation and long-term follow-up between adenoma and bilateral hyperplasia of the adrenal glands.

Authors:  T Jeck; B Weisser; T Mengden; L Erdmenger; S Grüne; W Vetter
Journal:  Clin Investig       Date:  1994-12

7.  Adrenalectomy in primary aldosteronism: a long-term follow-up study in 52 patients.

Authors:  G Favia; F Lumachi; V Scarpa; D F D'Amico
Journal:  World J Surg       Date:  1992 Jul-Aug       Impact factor: 3.352

Review 8.  Primary aldosteronism: a practical approach to diagnosis and treatment.

Authors:  R B Thakkar; S Oparil
Journal:  J Clin Hypertens (Greenwich)       Date:  2001 May-Jun       Impact factor: 3.738

Review 9.  Spironolactone: an old friend rediscovered.

Authors:  Domenic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-07       Impact factor: 3.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.